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Objective: We report an outbreak of Achromobacter xylosoxidans at a neonatal intensive care
unit.  We aimed to present clinical, laboratory and treatment data of the patients.
Materials and methods: All consecutive episodes of bacteremia due to A. xylosoxidans at our
neonatal  intensive care unit, beginning with the index case detected at November 2009 until
cessation of the outbreak in April 2010, were evaluated retrospectively.
Results:  Thirty-four episodes of bacteremia occurred in 22 neonates during a 6-month
period.  Among the affected, 90% were preterm newborns with gestational age of 32 weeks
or  less and 60% had birth weight of 1000 g or less. Endotracheal intubation, intravenous
catheter  use, total parenteral nutrition and prolonged antibiotic therapy were  the predis-
posing  conditions. Presenting features were abdominal distention, thrombocytopenia and
neutropenia. The mortality rate was 13.6% and the majority of isolates were susceptible to
piperacillin-tazobactam, carbapenems and trimethoprim-sulfametoxazole, and resistant to
gentamycin. More than half were breakthrough infections. Despite intensive efforts to con-
trol  the outbreak by standard methods of hand hygiene, patient screening and isolation,
containment  could be achieved only after the neonatal intensive care unit was relocated.
The  investigation was  not able to single out the source of the outbreak.Conclusion:  A. xylosoxidans has the potential to cause serious infections in premature babies.
More  studies are needed to determine the importance of different sources of infection in
hospital  units.
Yabuuchi and Ohyama  in 1971 from purulent ear discharge of
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negative bacillus which is widely distributed in nature,
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Este é um artigo Open Access sob a licençaespecially in aquatic environments.1,2 It was ﬁrst described byectious Diseases, Bezmialem Vakif University, Adnan Menderes
patients  with chronic otitis media.3 Since it is an opportunistic
pathogen it usually affects patients with underlying illnesses
and  immunosuppression.4,5 Infections such as bacteremia,
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neumonia, meningitis, urinary tract infections, abscesses,
steomyelitis, corneal ulcers, prosthetic valve endocarditis
nd  peritonitis have been reported.1,4–11 Treatment of Achro-
obacter infections is difﬁcult since the bacterium may  be
esistant  to several antibiotics.2
Because of limited data and lack of large series of infections
aused by Achromobacter in children, especially in newborns,
e  aimed to present an outbreak of A. xylosoxidans bacteremia
hat  took place at our neonatal intensive care unit (NICU).
ethods
he study was  performed in a level III neonatal reference unit
f  a tertiary care hospital where a mean of 400 newborns are
dmitted  annually. All consecutive episodes of bacteremia due
o A. xylosoxidans, beginning with the index case detected in
ovember  2009 until cessation of the outbreak in April 2010
ere  evaluated retrospectively. A case of A. xylosoxidans bac-
eremia  was  deﬁned as one or more  blood cultures positive for
. xylosoxidans when clinical signs of sepsis were  present.12
lood samples were  incubated into Bactec 9240 system (Bec-
on  Dickinson, USA) for up to seven days. A sample from
he  blood culture bottle with positive bacterial growth was
noculated  into 5% sheep blood agar and EMB (eosin methy-
ene  blue) agar (Oxoid, England), and incubated at 36.5 ◦C for
8–20  h. Gram negative bacilli with positive reaction for oxi-
ase  were  detected in Gram-stained smears prepared from
olonies.  Identiﬁcation of the microorganisms was  done by
PI  20 NE system (bioMerieux, France). Susceptibility of the
rganisms  to antimicrobial agents was  performed by using
Kirby–Bauer) disk-diffusion method on Mueller–Hinton agar,
ccording  to the Clinical Laboratory Standards Institute (CLSI)
uidelines.  Multiple episodes were indicated by the ﬁnding
f  A. xylosoxidans isolates in blood cultures obtained >four
eeks  apart, or >two weeks apart if the blood cultures became
terile  and/or there was  evidence of clinical resolution of the
nfection.4
Data recorded included sex, gestational age, birth weight,
ate  of admission, underlying diseases, presence of intravas-
ular  catheters, administration of broad-spectrum antibiotics
nd  total parenteral nutrition, number of positive blood cul-
ures  and sites of other cultures from which A. xylosoxidans
as  isolated. Neutropenia was  deﬁned as a count less than
.5  × 109/L cells/mm3, thrombocytopenia was  deﬁned as a
latelet  count of <80 × 109/L.13 Infections that occurred more
han  72 h after admission were  deﬁned as nosocomial.14
 breakthrough infection was  indicated by the isolation of
acteria  from blood cultures obtained while the patient was
eceiving  systemic antibiotics to which the bacteria was  later
onﬁrmed  to be susceptible.4
For the investigation of outbreak, bacteriological cultures
f  environmental samples were  taken including antiseptic
olutions (chlorhexidine digluconate, aqueous and alcoholic),
ash  basins, incubator surfaces, liquid soaps, faucets, neb-
lizators  and tap water. Hands of health care workers were
ampled  by direct ﬁngerprinting in Petri dishes. Fluids were
ltered  through 0.45 m membranes (Millipore, Bedford, MA,
SA)  and cultivated on sheep blood agar (SLB, Turkey), EMB
gar.  Swabs were  plated on EMB  agar and 5% sheep blood agar.3;1 7(4):450–454  451
Plates were incubated for 24 h at 36 ◦C. Environmental cultures
were  taken following detection of ﬁrst four bacteremia cases
in  November 2009 and discontinued after April 2010.
Results
Index  case
The index case was  a 25-week gestational age male (birth
weight  660 g) baby born to a G1P0A0 mother. After birth
he  was  intubated and transferred to the NICU with a diag-
nosis  of respiratory distress syndrome (RDS). He received
ampicillin-sulbactam and gentamycin since congenital pneu-
monia  could not be excluded. On the 7th day of life, minimal
enteral  feeding was  initiated but in the next day abdomi-
nal  distension developed and antibiotics were  switched to
vancomycin  and meropenem with a diagnosis of necrotiz-
ing  enterocolitis (NEC). Blood cultures remained sterile and
vancomycin  was  discontinued after 14 days. On 21st day of
meropenem  therapy, he developed apnea, leukopenia and
thrombocytopenia. He was  reintubated and meropenem was
switched  to sulbactam-cefoperazone and ﬂuconazole pend-
ing  culture results. His clinical condition deteriorated and he
developed acidosis, hypotension and bradycardia necessitat-
ing  a short duration of adrenalin infusion. Two sets of blood
cultures  yielded A. xylosoxidans susceptible to ciproﬂoxacin,
meropenem and trimethoprim-sulfametoxazole (TMP-SXM).
Sulbactam-cefoperazone and ﬂuconazole were  discontinued
and  meropenem plus ciproﬂoxacin were given. Blood cultures
became  sterile after ﬁve days. The patient’s clinical condition
resolved  gradually and he was extubated after seven days. He
was discharged from the NICU when at the age of two months.
Epidemiologic  investigation
Following the index case, four additional cases were  diag-
nosed  within the same week. An outbreak was  suspected
and  cohorting and contact precautions with gown  and glove
use  on entry to rooms of patients infected with A. xylosoxi-
dans  and enhanced environmental cleaning were  instituted.
An  investigation for determination of source of infection was
started.  Standard infection control practices such as hand
hygiene  (hand washing upon unit entry before and after
patient  contact and use of alcohol hand sanitizer between
patient contacts), aseptic technique for all invasive proce-
dures,  sterile procedures requiring gown, mask, and gloves
and  environmental cleaning were overviewed. Education of
healthcare  staff was  repeated but no ﬂaw was  found. Environ-
mental  vectors were  suspected and bacteriological cultures of
environmental  samples were taken but the source could not
be  identiﬁed. Twelve patients were determined to be infected
during  November and December. A second attack affecting 10
patients  was observed in March. Patients were transferred to
an other part of the hospital prepared as NICU in April. No
further  cases were detected during the following 12 months.Clinical  features  and  treatment  of  affected  neonates
A total of 22 neonates, 12 (54.5%) male, were  diagnosed
with A. xylosoxidans bacteremia. All infecting strains were
452  b r a z j i n f e c t d i s . 2 0
Table 1 – Characteristics of 22 newborns infected with
Achromobacter xylosoxidans.
Characteristic Value
Birth weight, mean ± SD 1197 ± 799 g
Gestational age, mean (range) 27.8 (23–37) weeks
Male/female 12/10
Age (days) at the time of diagnosis, mean (range) 21 (6–45)
Mortality, no. (%) 3 (13.6)
Predisposing factors (%)
Prematurity  100
Catheter 100
TPN 100
Previous broad spectrum antibiotic
administration
100
Diagnosis  at admission (%)
Prematurity  13.6
Prematurity + respiratory distress
syndrome (RDS)
72.7
Prematurity + RDS + digestive disorders 4.5
Other (chylothorax, hydrops fetalis, etc.) 9.1
Clinical ﬁndings at the time of diagnosis (%)
Fever 4.5
Abdominal distension 68.2
Apnea 45
Neutropenia 63.6
Thrombocytopenia 100
altered  consciousness. Dyspnea, abdominal pain, oliguria
and  diarrhea were also noted. In our study, thrombocytopeniaBreakthrough infection (%) 63.6
considered nosocomially acquired. All patients were  preterm
and 60% were  under 1000 g birth weight. Prematurity and
respiratory distress syndrome (RDS) were the most common
diagnosis at admission. Most common presenting features
of  infection were  abdominal distention, apnea, thrombocy-
topenia and leukopenia (Table 1). Three out of 22 patients
had  cerebrospinal ﬂuid (CSF) abnormalities suggestive of bac-
terial meningitis and A. xylosoxidans growth was  detected
in  CSF in addition to blood culture. 84% of patients recov-
ered  with antibiotic therapy while three patients died due
to  Achromobacter sepsis. Two patients had multiple growths
of  A. xylosoxidans. In vitro susceptibility proﬁle of A. xylosox-
idans  isolates to antimicrobial agents is given in Table 2.
Breakthrough infection was  observed in 14 patients (63.6%).
Patients  received 10–21 day course of meropenem alone
(9.7%),  meropenem in combination with other antibiotics
(meropenem plus ciproﬂoxacin, meropenem plus ceftazidime
and  meropenem plus piperacillin-tazobactam in 50%, 22.7%,
Table 2 – In vitro susceptibility proﬁle of 34 Achromobacter xylos
Antimicrobial agent 
Susceptible (%) 
Trimethoprim-sulfametoxazole (TMP-SXM) 100 
Meropenem 100 
Piperacillin-tazobactam 91 
Ciproﬂoxacin 82 
Ceftazidime 82 
Cefepime 15 
Gentamycin 0  1 3;1  7(4):450–454
and 13.6% of patients, respectively) or ciproﬂoxacin plus cef-
tazidime  (4.5%).
Discussion
A. xylosoxidans is an emerging nosocomial pathogen. It repre-
sented  12.5% of nonfermenting Gram negative bacilli isolated
in  Latin America medical centers during SENTRY program
1997–2002.15 Respiratory tract colonization in cystic ﬁbrosis
patients has also been recognized during the last decade.16
Case reports due to A. xylosoxidans infection in Turkey are
increasingly reported.17–19 Nevertheless, knowledge about
neonatal infections caused by A. xylosoxidans is relatively
scarce. It was reported as a contaminant leading to pseu-
dobacteremia outbreak at NICU but serious infections such
as  meningitis and fatal sepsis in prematures were also
described.6,20–22
A. xylosoxidans bacteremia is almost always a nosoco-
mial infection.23 Bacteremia due to A. xylosoxidans is usually
related  to intravascular catheters and is frequently polymicro-
bial  in patients with underlying malignancies.4,24 Shie et al.
evaluated  characteristics of A. xylosoxidans bacteremia in Tai-
wan  and reported that malignancies, central venous catheter
implants  and previous major surgery were the most com-
mon  underlying conditions.25 Another study in a tertiary care
hospital  in India identiﬁed 20 strains of A. xylosoxidans iso-
lated  from 15 patients during one year period.26 Seventeen
isolates were  from blood, two from CSF and one from pleural
ﬂuid;  30% of patients were premature neonates. We  identi-
ﬁed  low birth weight, prematurity, total parenteral nutrition
(TPN)  and previous broad spectrum antibiotic therapy as the
major  predisposing conditions for Achromobacter bacteremia
in  our study. 4.5% of patients had undergone surgical interven-
tions.  The mean interval from hospital admission to isolation
of  a positive culture was  21 days. All affected neonates had
umbilical  catheter insertion and in all bacteremia episodes A.
xylosoxidans  was  isolated as the sole pathogen.
Aisenberg et al. reported that Achromobacter bacteremia
presented with fever (52%), sepsis syndrome (22%) and respi-
ratory  complaints (17%).4 In another report of 40 cases of
A.  xylosoxidans bacteremia, the most common manifesta-
tions were fever (82%), chills (37.5%), hypotension (32.5%) and
25(100%), neutropenia (63.6), abdominal distension (69%) and
apnea  (45%) were the most common clinical features. These
oxidans isolates to antimicrobial agents.
Number of isolates (n = 34)
Intermediately susceptible (%) Resistant (%)
0 0
0 0
3 6
15 3
3 15
9 76
0 100
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ndings are common with other Gram negative bacilli and
ungi  septicemia which makes the diagnosis rather difﬁcult
nless  proven by culture. Fever was  reported less frequently
4.5%)  probably because of insufﬁcient immune response of
remature  neonates. Three deaths were attributable to A.
ylosoxidans  sepsis with a fatality rate lower than previous
eports (15–47.5%).4,23,25
There have been many  reports of A. xylosoxidans isolation
rom  environmental sources in hospital acquired infections.23
. xylosoxidans was  detected in deionized water in an intensive
are  unit and tap water and on the hands of two health care
orkers  in a hemodialysis unit.1,23 We  checked environmental
amples and hands of healthcare personnel for colonization
ut  were  unable to determine the source. In a similar report
rom  India, Kumar et al. were  also unable to determine the
ource.26 Since there was  similarity of antibiotic susceptibility
attern of isolates, probable clonality of the isolates could be
redicted but we were  unable to perform testing for molecular
pidemiology. In addition to enhanced infection control meas-
res  and increased awareness of health care staff, decreased
atient  capacity during the ﬁrst days following relocation of
ICU  may  have prevented development of additional cases of
.  xylosoxidans bacteremia.
A.  xylosoxidans has an unusual susceptibility pattern with
esistance to aminoglycosides and to the majority of -lactam
ntibiotics. Anti-pseudomonal penicillins, TMP-SMZ and car-
apenems  are the preferred agents in treatment.2,27 All of
ur  isolates were  sensitive to TMP-SXM and meropenem
nd the majority were sensitive to piperacillin-tazobactam
imilar to previous reports. Susceptibility to the ﬂuoro-
uinolones is variable.28 Gomez et al. and Almuzara et al.
ave  reported that quinolones have poor activity against
chromobacter spp.23,29 In contrast 82% of our isolates
ere  susceptible to ciproﬂoxacin. For infections caused by
ultidrug-resistant A. xylosoxidans, antimicrobial combina-
ions  such as piperacillin plus gentamycin, azitromycin plus
oxycycline,  and azitromycin plus TMP-SXM have been tested
ith  favorable results.24 Since 63% of infections were deﬁnite
reakthrough infections and the patients were severely ill we
sed combination therapy in most patients.
onclusion
. xylosoxidans has the potential to cause serious infections in
ospitalized neonates. Antimicrobial susceptibility proﬁle for
ach case should be taken into account for determining the
herapy.  More  studies are needed to assess the importance of
ifferent  sources of contamination in hospital units.
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